Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates

Ralph A. DeFronzo, Devjit Tripathy, Dawn C. Schwenke, Mary Ann Banerji, George A. Bray, Thomas A. Buchanan, Stephen C. Clement, Amalia Gastaldelli, Robert R. Henry, Abbas E. Kitabchi, Sunder Mudaliar, Robert E. Ratner, Frankie B. Stentz, Nicolas Musi, Peter D. Reaven

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/ insulin resistance (IR; ΔI0-120 /ΔG0-120, ΔIS rate [ISR] 0-120/ΔG0-120), and β-cell function (ΔI /ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15-0.49]; P < 0.0001); 48% of PGZtreated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54- 0.80]), IS (OR 0.61 [95% CI 0.50-0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19-0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.

Original languageEnglish (US)
Pages (from-to)3920-3926
Number of pages7
JournalDiabetes
Volume62
Issue number11
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

pioglitazone
Insulin
Odds Ratio
Insulin Resistance
Glucose Intolerance
Placebos
Glucose
C-Peptide
Glucose Tolerance Test
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M. A., Bray, G. A., Buchanan, T. A., ... Reaven, P. D. (2013). Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates. Diabetes, 62(11), 3920-3926. https://doi.org/10.2337/db13-0265

Prevention of diabetes with pioglitazone in ACT NOW : Physiologic correlates. / DeFronzo, Ralph A.; Tripathy, Devjit; Schwenke, Dawn C.; Banerji, Mary Ann; Bray, George A.; Buchanan, Thomas A.; Clement, Stephen C.; Gastaldelli, Amalia; Henry, Robert R.; Kitabchi, Abbas E.; Mudaliar, Sunder; Ratner, Robert E.; Stentz, Frankie B.; Musi, Nicolas; Reaven, Peter D.

In: Diabetes, Vol. 62, No. 11, 01.11.2013, p. 3920-3926.

Research output: Contribution to journalArticle

DeFronzo, RA, Tripathy, D, Schwenke, DC, Banerji, MA, Bray, GA, Buchanan, TA, Clement, SC, Gastaldelli, A, Henry, RR, Kitabchi, AE, Mudaliar, S, Ratner, RE, Stentz, FB, Musi, N & Reaven, PD 2013, 'Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates', Diabetes, vol. 62, no. 11, pp. 3920-3926. https://doi.org/10.2337/db13-0265
DeFronzo RA, Tripathy D, Schwenke DC, Banerji MA, Bray GA, Buchanan TA et al. Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates. Diabetes. 2013 Nov 1;62(11):3920-3926. https://doi.org/10.2337/db13-0265
DeFronzo, Ralph A. ; Tripathy, Devjit ; Schwenke, Dawn C. ; Banerji, Mary Ann ; Bray, George A. ; Buchanan, Thomas A. ; Clement, Stephen C. ; Gastaldelli, Amalia ; Henry, Robert R. ; Kitabchi, Abbas E. ; Mudaliar, Sunder ; Ratner, Robert E. ; Stentz, Frankie B. ; Musi, Nicolas ; Reaven, Peter D. / Prevention of diabetes with pioglitazone in ACT NOW : Physiologic correlates. In: Diabetes. 2013 ; Vol. 62, No. 11. pp. 3920-3926.
@article{6518b02333a348e39c6e2f6717f39369,
title = "Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates",
abstract = "We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/ insulin resistance (IR; ΔI0-120 /ΔG0-120, ΔIS rate [ISR] 0-120/ΔG0-120), and β-cell function (ΔI /ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95{\%} CI 0.15-0.49]; P < 0.0001); 48{\%} of PGZtreated subjects reverted to normal glucose tolerance (NGT) versus 28{\%} of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95{\%} CI 0.54- 0.80]), IS (OR 0.61 [95{\%} CI 0.50-0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95{\%} CI 0.19-0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.",
author = "DeFronzo, {Ralph A.} and Devjit Tripathy and Schwenke, {Dawn C.} and Banerji, {Mary Ann} and Bray, {George A.} and Buchanan, {Thomas A.} and Clement, {Stephen C.} and Amalia Gastaldelli and Henry, {Robert R.} and Kitabchi, {Abbas E.} and Sunder Mudaliar and Ratner, {Robert E.} and Stentz, {Frankie B.} and Nicolas Musi and Reaven, {Peter D.}",
year = "2013",
month = "11",
day = "1",
doi = "10.2337/db13-0265",
language = "English (US)",
volume = "62",
pages = "3920--3926",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Prevention of diabetes with pioglitazone in ACT NOW

T2 - Physiologic correlates

AU - DeFronzo, Ralph A.

AU - Tripathy, Devjit

AU - Schwenke, Dawn C.

AU - Banerji, Mary Ann

AU - Bray, George A.

AU - Buchanan, Thomas A.

AU - Clement, Stephen C.

AU - Gastaldelli, Amalia

AU - Henry, Robert R.

AU - Kitabchi, Abbas E.

AU - Mudaliar, Sunder

AU - Ratner, Robert E.

AU - Stentz, Frankie B.

AU - Musi, Nicolas

AU - Reaven, Peter D.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/ insulin resistance (IR; ΔI0-120 /ΔG0-120, ΔIS rate [ISR] 0-120/ΔG0-120), and β-cell function (ΔI /ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15-0.49]; P < 0.0001); 48% of PGZtreated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54- 0.80]), IS (OR 0.61 [95% CI 0.50-0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19-0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.

AB - We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/ insulin resistance (IR; ΔI0-120 /ΔG0-120, ΔIS rate [ISR] 0-120/ΔG0-120), and β-cell function (ΔI /ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15-0.49]; P < 0.0001); 48% of PGZtreated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54- 0.80]), IS (OR 0.61 [95% CI 0.50-0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19-0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.

UR - http://www.scopus.com/inward/record.url?scp=84891696888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891696888&partnerID=8YFLogxK

U2 - 10.2337/db13-0265

DO - 10.2337/db13-0265

M3 - Article

C2 - 23863810

AN - SCOPUS:84891696888

VL - 62

SP - 3920

EP - 3926

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -